Case report

*Campylobacter fetus* aortitis in a patient with HIV

Uzoamaka A. Eke*1, James B. Doub, Joel V. Chua

Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA

**Abstract**

A 36-year-old man with well controlled HIV developed *Campylobacter fetus* aortitis. To prevent aortic rupture, emergent surgical resection and neo-aortoiliac replacement with his left femoral vein was conducted. After surgical intervention, he was successfully treated with intravenous ertapenem for 6 weeks followed by oral amoxicillin for 3 months.

© 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

**Introduction**

Infective aortitis is a rare life-threatening condition that is usually secondary to microbial seeding of the aortic adventitia during bacteremia [1]. Symptoms are nonspecific including fever, abdominal pain, and back pain. Given the nonspecific clinical symptoms, aortitis can be difficult to diagnose thereby leading to complications including sepsis and aneurysm formation that can rapidly progress to aortic rupture [1–3]. Computerized topography (CT) is the diagnostic imaging of choice to aid in diagnosing this condition. During the pre-antimicrobial era, infective aortitis was largely a complication of endocarditis caused by *Streptococcus* and *Hemophilus* [1]. More recently, *Staphylococcus* has become the predominant pathogen in part due to intravascular procedures and injection drug use [1,4]. Enterobacteriaceae are occasional pathogens with *Salmonella* being the most prevalent gram-negative bacteria accounting for approximately 15 % of cases [4,5]. Other rare pathogens include *Treponema*, *Listeria*, and *Aspergillus* [4–6]. Treatment involves surgical resection of infected aortic tissue with aortic reconstruction in combination with aggressive antimicrobial therapy. We present a rare case of a patient with human immunodeficiency virus-1 (HIV) infection who developed *Campylobacter fetus* aortitis that was successfully treated with emergent surgical intervention and six weeks of intravenous ertapenem followed by three months of oral amoxicillin therapy.

* Corresponding author at: Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, 725 West Lombard Street, Baltimore, MD 21201, USA.

E-mail address: UEke@hiv.umaryland.edu (U.A. Eke).

**Case report**

A 36-year-old man with well controlled HIV, on abacavir-lamivudine-dolutegravir (CD4 count of 931 cells/μL with undetectable viral load), presented with a one-week history of lower abdominal pain radiating to his back. He initially attributed the pain to constipation but when the pain progressed, he decided to seek medical advice at a local emergency room. CT scan of the abdomen and pelvis with oral and intravenous contrast showed an ill-defined infrarenal peri-aortic mass with an adjacent eccentric thrombus in the abdominal aorta and subtle enhancement of the vasa vasorum concerning for focal aortitis (Fig. 1). Initial concern was for a neoplastic process and outpatient CT guided biopsy was scheduled, but symptoms intensified over ten days prompting further medical evaluation. CT angiogram of the chest and abdomen showed a pseudoaneurysm of the aorta (Fig. 2A) and a focal dissection extending to the aortic bifurcation (Fig. 2B). Given these findings, the patient was transferred to our tertiary care center for further surgical and medical management.

On arrival the patient was hemodynamically stable with no fever or chills. He did recall a brief transient febrile illness with malaise two months prior but denied any other symptoms at that time. The patient denied any history of vascular disease, endovascular infections, or injection drug use. He was in a monogamous relationship with his male sexual partner who also had well controlled HIV on antiretroviral therapy. However, his sexual partner did have a recurrent diarrheal illness over the past four months requiring repeated oral antimicrobial courses. Physical examination was unremarkable except for tenderness to direct palpation on all four abdominal quadrants. Laboratory data was remarkable for WBC of 23,200 cells/μL (normal range 4,500–11,000 cells/μL) with 85 % neutrophils, erythrocyte
A pseudoaneurysm. His blood results showed an abnormal sedimentation rate of 67 mm/hour (normal range 0–15 mm/hour), and a C-reactive protein of 3.7 mg/dl (normal value <1 mg/dl). Blood cultures had no growth and rapid plasma reagin was nonreactive. Transthoracic echocardiogram did not have any abnormalities. Given the concern for infective aortitis, the patient was started on intravenous vancomycin 1.75 g every 12 h and piperacillin-tazobactam 4.5 g every six hours.

The patient underwent an emergent aortic repair and resection of the inferior abdominal aorta and neo-aortoiliac replacement with his left femoral vein. Intraoperatively, marked retroperitoneal edema, inflammation, and severe adhesions were observed around the distal aorta. Pathological evaluation of his resected abdominal aorta showed acute and chronic adventitial inflammation with pseudoaneurysm. Aortic tissue culture grew *C. fetus* and susceptibility testing was sent to a reference lab with results seen in Table 1. His postoperative course was unremarkable and he was discharged home on intravenous ertapenem 1 g daily. He completed a 6-week course of intravenous ertapenem therapy without any side effects and then was transitioned to oral amoxicillin 500 mg twice a day for three months. Following the completion of therapy, the patient

---

**Table 1**

| Antimicrobial | MIC μg/mL^* |
|---------------|-------------|
| Ampicillin    | 1           |
| Ceftriaxone   | 2           |
| Gentamicin    | 0.5         |
| Meropenem     | <0.06       |

MIC: minimum inhibitory concentration.

^At the present time, there are no clinical and laboratory standards institute (CLSI) guidelines for the interpretation of these MICs of *C. fetus* susceptibility to these antimicrobials.
has continued to do well and remains symptom free, off antimicrobial therapy.

Discussion

Campylobacteriosis is a bacterial gastrointestinal illness causing an estimated 1.3 million diarrheal illnesses annually [7]. *Campylobacter* spp. are microaerophilic, nonfermenting gram-negative bacteria. There are over 20 species of *Campylobacter* but *C. jejuni*, *C. coli* and *C. fetus* are the predominant species implicated in human infections. *C. fetus* is primarily a zoonotic pathogen that rarely causes human infections, accounting for less than 3% of all campylobacter diarrheal illnesses but over 50% of invasive campylobacteriosis, with a mortality rate up to 14% [8,9]. Humans usually contract *C. fetus* through the fecal-oral route, with some association to consumption of raw beef, raw liver, and cheese [8]. Immunosuppression and older age are known risk factors for invasive *C. fetus* infections [8]. However, there is a paucity of data on invasive *C. fetus* in HIV patients and to our knowledge this is the first reported case of *C. fetus* aortitis in a patient with HIV.

This patient did not present with the characteristic gastrointestinal symptoms that are typical with campylobacteriosis, but his transient febrile illness two months prior to presentation may have represented *C. fetus* bacteremia and subsequent seeding of his abdominal aorta. He likely acquired his infection fecal-oral given that his male sexual partner had recurrent enteritis that may have been due to *C. fetus* as well. This is not surprising because *C. fetus* clusters have been identified among men who have sex with men [10,11].

*C. fetus* aortitis characteristically has rapid progression to aneurysm formation and subsequently, to aortic rupture. Overall mortality of *C. fetus* aortitis is 20–30% but mortality approaches 100% if rupture occurs before surgical intervention can be conducted [10–12]. Our case illustrates the rapid progression of *C. fetus* from focal aortitis (Fig. 1) to the development of pseudoaneurysm over ten days (Fig. 2). Once the pseudoaneurysm was identified, emergent open resection and neo-aortoiliac replacement with his left femoral vein was conducted. This case reinforces the need for a high index of suspicion to identify and surgically treat *C. fetus* aortitis, thereby preventing progression to aortic rupture and reducing mortality.

While surgical resection is paramount, persistence and aptness to evade the immune system by *C. fetus* predisposes patients to a high risk for recurrence even after aggressive surgical and medical management. This can be attributed to *C. fetus*’ paracrystalline surface layer comprised of high molecular weight surface layer proteins (SLPs) which allows the organism to evade compliment binding and subsequent compliment-mediated destruction in non-immune serum [13]. Although antibodies are active against the SLPs, the SLPs can develop high frequency antigenic variations that can evade opsonization and antibody-dependent phagocytosis [14]. By so doing, *C. fetus* can evade both innate and adaptive immunity leading to persistent and relapsing infections. In addition, *C. fetus* has a tropism for endothelial surfaces due to high affinity binding of its surface receptor to the vascular endothelium and the release of pro-coagulants that promote intravascular thrombosis [8]. This is supported by case series reporting high rates of aortic aneurysms in patients with *C. fetus* bacteremia [10,11].

The ability of *C. fetus* to evade the immune system and its predilection for recurrence complicates treatment which leads to a wide variety of treatment durations ranging from six weeks to lifelong oral antibacterial suppression after intravenous antibiotics [10,12]. While macrolides remain the drug of choice for noninvasive *C. fetus* infections, the optimal therapy for invasive disease has not been established [15]. Third generation cephalosporins are the agents of choice against invasive salmonellosis, but they are not bactericidal against *C. fetus* and have high rates of resistance [16]. Therefore, carbapenems and aminoglycosides are commonly used for invasive *C. fetus* disease given that these agents are bactericidal, have low MICs, and have had successful clinical outcomes as documented in different case series and reports [9–11]. Furthermore, fluoroquinolones should be used with caution given the increased rates of resistance, but amoxicillin and ampicillin have documented bactericidal activity especially at high concentrations [8,9]. Based on this data, we treated our patient with six weeks of a carbapenem, using intravenous carbenapen therapy rests on individualized treatment decisions that consider the severity of underlying immunodeficiencies and other host factors rather than standardized protocols for all. Therefore given his underlying HIV which was well controlled, we elected to treat with oral amoxicillin for three months similar to other documented regimens in patients with underlying conditions [12].

Immunocompromised patients are theorized to be more susceptible to invasive *C. fetus* infections secondary to impaired cell-mediated and humoral immunity compared to immunocompetent hosts. In one cohort, HIV infection was associated with up to a 40-fold increase in the incidence of severe, chronic and recurrent campylobacteriosis compared to non-HIV individuals [19]. This is likely secondary to the HIV, which impairs not only cell mediated immunity, but also creates a dysregulated humoral response, with reduced ability to produce effective pathogen-specific antibodies, especially to encapsulated pathogens [20,21]. In addition, HIV has also been shown to cause a depressed production of mucosal secretory IgA and abnormally low campylobacter-specific IgA, IgM, and IgG antibodies in HIV patients with recurrent, invasive infections compared to those patients who did not experience relapse [22,23]. Therefore, in the HIV-infected patient, *C. fetus* appears to be a very elusive pathogen that has the ability to evade the host’s innate and adaptive immunity with its SLPs acting as a proteinaceous capsule [14]. In our patient, he had well controlled HIV with CD4 count of 931 cells/μL and HIV viral load that was undetectable, but given the concern for recurrence, we treated him with oral amoxicillin for three months after he had received six weeks of intravenous ertapenem. He will continue to follow with infectious diseases to ensure that there is no clinical recurrence and that he continues to be compliant with antiretroviral therapy for his underlying HIV infection.

Conclusion

To our knowledge, this is the first case report of *C. fetus* aortitis in a HIV-infected patient. He was successfully treated with surgical resection of the pseudoaneurysm and a six-week course of intravenous ertapenem followed by three months of oral amoxicillin therapy given his underlying immunosuppression. This case reinforces the need for prompt surgical and medical treatment of this rare infection to prevent devastating aortic rupture. Further studies are needed to clarify the pathophysiology of the deficient innate and acquired immune responses that are associated with *C. fetus* invasive infections. This may help determine the proper duration of antimicrobial therapy. However, given the rarity and heterogeneity with respect to the immune statuses of infected hosts, the duration of antimicrobial therapy will likely have to be individualized rather than standardized.

Conflicts of interest

The authors have nothing to disclose.
Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors

Consent

Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request

Ethical approval

Not applicable because it is a case report.

Author contribution

Uzoamaka A. Eke: Conceptualization, Writing-original draft preparation, reviewing and editing. Joel V. Chua: Writing-reviewing and editing.

References

[1] Foote EA, Postier RG, Greenfield RA, Bronze MS. Infectious aortitis. Curr Treat Options Cardiovasc Med 2005;7(2):89–97.
[2] Oderich GS, Panneton JM, Bower TC, et al. Infected aortic aneurysms: aggressive presentation, complicated early outcome, but durable results. J Vasc Surg 2001;34(5):900–8.
[3] Deiopoloi AR, Czaplicki CD, Oklu R. Inflammatory and infectious aortic diseases. Cardiovasc Diagn Ther 2018;8(Suppl 1):S61–S70.
[4] Brown SL, Busuttil RW, Baker JD, Mackleder HI, Moore WS, Barker WF. Bacteriologic and surgical determinants of survival in patients with mycotic aneurysms. J Vasc Surg 1984;1(4):541–7.
[5] Müller BT, Wegener OR, Grabitz K, Pillny M, Thomas L, Sandmann W. Mycotic aneurysms of the thoracic and abdominal aorta and iliac arteries: experience with anatomic and extra-anatomic repair in 33 cases. J Vasc Surg 2001;33(1):106–13.
[6] Maeda H, Umezawa H, Goshima M, et al. Primary infected abdominal aortic aneurysm: surgical procedures, early mortality rates, and a survey of the prevalence of infectious organisms over a 30-year period. Surg Today 2011;41(3):346–51.
[7] Tack DM, Ray L, Griffin PM, et al. Preliminary incidence and trends of infections with pathogens transmitted commonly through food - Foodborne Diseases Active Surveillance Network, 10 U.S. Sites, 2016–2019. MMWR Morb Mortal Wkly Rep 2020;69(17):509–14.
[8] Wagenaar JA, van Bergen MA, Blaser MJ, Tauxe RV, Newell DG, van Putten JP. Campylobacter fetus infections in humans: exposure and disease. Clin Infect Dis 2014;58(11):1579–86.
[9] Tremblay C, Gaudreau C, Lorange M. Epidemiology and antimicrobial susceptibilities of 111 Campylobacter fetus subsp. Fetus strains isolated in Quebec, Canada, from 1983 to 2000. J Clin Microbiol 2003;41(1):463–6.
[10] Cochenneve F, Gazeigne L, Lesprit P, Desgranges P, Allaire E, Becquemin JP. Aortoaortic aneurysms infected by Campylobacter fetus. J Vasc Surg 2008;4(8):815–20.
[11] Gazeigne I, Legrand P, Renaud B, et al. Campylobacter fetus bloodstream infection: risk factors and clinical features. Eur J Clin Microbiol Infect Dis 2008;27(3):185–9.
[12] Rutherford RJ, Eakins JW, Maxwell JG, Tackett AD. Abdominal aortic aneurysm infected with Campylobacter fetus subspecies fetus. J Vasc Surg 1989;10(2):193–7.
[13] Thompson SA, Shedd OL, Ray KC, Beins MH, Jorgensen JP, Blaser MJ. Campylobacter fetus surface layer proteins are transported by a type I secretion system. J Bacteriol 1998;180(24):6540–8.
[14] Blaser MJ, Smith PF, Hopkins JA, Heimner I, Bynner JT, Wang WL. Pathogenesis of Campylobacter fetus infections: serum resistance associated with high-molecular-weight surface proteins. J Infect Dis 1987;155(4):696–706.
[15] Geissler AL, Bustos Cyrillo F, Swanson K, et al. Increasing campylobacter infections, outbreaks, and antimicrobial resistance in the United States, 2004–2012. Clin Infect Dis 2017;65(10):1624–31.
[16] Wieczorek K, Osek J. Antimicrobial resistance mechanisms among Campylobacter. Biomed Res Int 2013:2013:340650.
[17] Ghimire R, Urban C, Lee A, Pokhrel A, Wehbeh W, Turett G. Campylobacter fetus infection of the aorta: a case report and review of literature. Am J Infect Dis 2015;11(2):26–32.
[18] Melendez BA, Hollis Jr. HW, Rehring TF. Mycotic popliteal aneurysm rupture secondary to Campylobacter fetus. Ann Vasc Surg 2015;29(1):122.e9–11.
[19] Sorvillo FJ, Lieb LE, Waterman SH. Incidence of campylobacteriosis among patients with AIDS in Los Angeles County. J Acquir Immune Defic Syndr (1988) 1991;4(5):598–602.
[20] Müller F, Froiland SS, Hvatum M, RadJ, Brandzaeg P. Both IgA subclasses are reduced in parotid saliva from patients with AIDS. Clin Exp Immunol 1991;83(2):203–9.
[21] Carson PJ, Schut RL, Simpson ML, O’BrienJ, Janoff EN. Antibody class and subclass responses to pneumococcal polysaccharides following immunization of human immunodeficiency virus–infected patients. J Infect Dis 1995;172(2):340–5.
[22] Bernard E, Roger PM, Carles D, Bonal Di, Fournier JP. Dellamonica P. Diarrhea and Campylobacter infections in patients infected with the human immunodeficiency virus. J Infect Dis 1989;159(1):143–4.
[23] Perlman DM, Ampel NM, Schifman RB, et al. Persistent Campylobacter jejuni infections in patients infected with the human immunodeficiency virus (HIV). Ann Intern Med 1988;108(4):540–6.